Clinical Chemistry Siemens Point of Care - Urinalysis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 44: 2103-2107, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (29)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berndt, C.
Right arrow Articles by Zanow, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berndt, C.
Right arrow Articles by Zanow, J.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 1998;44:2103-2107.)
© 1998 American Association for Clinical Chemistry, Inc.

Molecular Diagnostics and Genetics

K-ras mutations in stools and tissue samples from patients with malignant and nonmalignant pancreatic diseases

Christoph Berndt1,a, Katrin Haubold2, Frank Wenger2, Brigitte Brux1, Joachim Müller2, Peter Bendzko3, Timo Hillebrand3, Eckhard Köttgen1, and Jürgen Zanow2,1

1 Institute of Laboratory Medicine and Pathobiochemistry and
2 Clinic of Surgery, Medical Faculty Charité, Humboldt-University, Schumannstrasse 20/21, D-10117 Berlin, Germany.

3 InViTek GmbH, Berlin Buch, 10362 Berlin, Germany.
a Address correspondence to this author at: Universitätsklinikum Charité, Campus Charité-Mitte, Institut für Laboratoriumsmedizin und Pathobiochemie, Schumannstrasse 20/21, 10098 Berlin, Germany. Fax 049-30-2802-1400; e-mail christoph.berndt{at}charite.de.

Mutant-enriched PCR and reverse dot blot hybridization in microplates were applied for examining K-ras status in stools and tissue samples from patients with pancreatic tumors and chronic pancreatitis. In tissue samples, K-ras mutations were found in 32 of 35 cases of ductal adenocarcinoma, in 5 of 7 periampullary cancers, in 1 cystadenocarcinoma, and in 3 of 5 patients with chronic pancreatitis. In stools, mutated K-ras was seen in 10 of 25 cases of ductal adenocarcinoma, in 1 case of cystadenocarcinoma, and in 2 of 6 cases of chronic pancreatitis. These data indicate that the K-ras status of stool samples may help identify pancreatic carcinoma and persons at risk for cancer development; however, it does not allow discrimination of malignant from nonmalignant diseases.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
U. Haug, T. Hillebrand, P. Bendzko, M. Low, D. Rothenbacher, C. Stegmaier, and H. Brenner
Mutant-Enriched PCR and Allele-Specific Hybridization Reaction to Detect K-ras Mutations in Stool DNA: High Prevalence in a Large Sample of Older Adults
Clin. Chem., April 1, 2007; 53(4): 787 - 790.
[Abstract] [Full Text] [PDF]

Home page
 Annals of Clinical & Laboratory ScienceHome page
Y. Kim, S. Lee, S. Park, H. Jeon, W. Lee, J. K. Kim, M. Cho, M. Kim, J. Lim, C. S. Kang, et al.
Gastrointestinal Tract Cancer Screening Using Fecal Carcinoembryonic Antigen
Ann. Clin. Lab. Sci., January 1, 2003; 33(1): 32 - 38.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
I F C McKENZIE and V APOSTOLOPOULOS
Towards immunotherapy of pancreatic cancer
Gut, June 1, 1999; 44(6): 767 - 769.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.